Chapter 33.Lurasidone
Sections
Excerpt
Lurasidone (Latuda), one of the most recent additions to the atypical antipsychotic class, received U.S. Food and Drug Administration (FDA) approval for the treatment of schizophrenia in October 2010 and for the treatment of bipolar depression in June 2013. As with all currently registered antipsychotic medications, lurasidone is a dopamine D2 receptor antagonist. In addition, this compound is a full antagonist at the serotonin 2A (5-HT2A) receptor, similar to other atypical antipsychotic medications. Lurasidone has other receptor affinities that may contribute to additional beneficial or adverse effects. Because lurasidone is relatively new, its database is limited compared with that of other medications, although the recently approved indication for bipolar depression has led to several additional publications. A current interesting line of investigation is lurasidone’s potential utility in the treatment of a new entity defined in DSM-5 (American Psychiatric Association 2013), bipolar depression with mixed features.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
